Sixteen Indian pharma firms have been blacklisted by Nepal’s drug regulatory authority for his or her “failure” to adjust to the World Health Organization’s drug manufacturing requirements, media experiences claimed on Tuesday.

In a discover issued on December 18, the Department of Drug Administration requested the native brokers in Nepal, which have been supplying these medicines, to instantly recall them. The discover additionally mentions the names of pharma firms blacklisted (each Indian and overseas), and says that medicines manufactured by the listed firms can’t be imported or distributed in Nepal.

Also learn | IMA slams Patanjali campaign as breach of medical ethics

Apart from Divya Pharmacy, which manufactures Yoga Guru Ramdev’s Patanjali merchandise, the checklist additionally consists of Radiant Parenterals Ltd, Mercury Laboratories Ltd, Alliance Biotech, Captab Biotec, Aglowmed Ltd, Zee Laboratories, Daffodils Pharmaceuticals, GLS Pharma, Unijules Life Science, Concept Pharmaceuticals, Shree Anand Life Sciences, IPCA laboratories, Cadila Healthcare Ltd, Dial Pharmaceuticals and Mackur laboratories. The checklist additionally names a number of overseas manufacturers.

According to information company PTI, the checklist was printed after an inspection of the manufacturing services of the pharmaceutical firms that had utilized to export their merchandise to Nepal. The division had – in April and July – despatched a staff of drug inspectors to India to examine the manufacturing services of pharmaceutical firms that had utilized to produce their merchandise to Nepal.

Earlier, the WHO issued a medical product alert over four cough syrups — Promethazine Oral Solution, Kofexmalin Baby Cough Syrup, Makoff Baby Cough Syrup, and Magrip N Cold Syrup — manufactured and exported by India’s Maiden Pharma. The 4 cough syrups have been mentioned to be linked to no less than 66 deaths of youngsters in The Gambia.

(With PTI, bureau inputs)